BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34570257)

  • 21. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
    Lee JW; Na JO; Kang DY; Lee SY; Lee SM
    Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of thoracic tumor staging and volume parameters in non-small cell lung cancer patients with synchronous solitary bone metastasis.
    Deng K; Li S; Zhang J; Ye X; Yao K; Li Y; Xiao J
    J Thorac Dis; 2022 Apr; 14(4):1130-1138. PubMed ID: 35572912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).
    Agarwal M; Brahmanday G; Bajaj SK; Ravikrishnan KP; Wong CY
    Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):691-8. PubMed ID: 19915840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of volumetric metabolic parameter changes determined by during and after radiotherapy-based
    Chen HHW; Su WC; Guo HR; Lee BF; Chiu NT
    Kaohsiung J Med Sci; 2019 Mar; 35(3):151-159. PubMed ID: 30887722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of various semiquantitative parameters of 18F-FDG PET/CT studies for interim treatment response evaluation in non-small-cell lung cancer.
    Sharma A; Mohan A; Bhalla AS; Vishnubhatla S; Pandey AK; Bal CS; Kumar R
    Nucl Med Commun; 2017 Oct; 38(10):858-867. PubMed ID: 28817456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developing a clinical and PET/CT volumetric prognostic index for risk assessment and management of NSCLC patients after initial therapy.
    Liu L; Zhang J; Ferguson MK; Appelbaum D; Zhang JX; Pu Y
    Front Biosci (Landmark Ed); 2022 Jan; 27(1):16. PubMed ID: 35090321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thoracic staging with
    Schaarschmidt BM; Grueneisen J; Metzenmacher M; Gomez B; Gauler T; Roesel C; Heusch P; Ruhlmann V; Umutlu L; Antoch G; Buchbender C
    Eur Radiol; 2017 Feb; 27(2):681-688. PubMed ID: 27180186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer.
    Hyun SH; Ahn HK; Kim H; Ahn MJ; Park K; Ahn YC; Kim J; Shim YM; Choi JY
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):50-8. PubMed ID: 23948859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer.
    Oh JR; Seo JH; Chong A; Min JJ; Song HC; Kim YC; Bom HS
    Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):925-35. PubMed ID: 22270509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic tumor burden on postsurgical PET/CT predicts survival of patients with gastric cancer.
    Sun G; Cheng C; Li X; Wang T; Yang J; Li D
    Cancer Imaging; 2019 Mar; 19(1):18. PubMed ID: 30902116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of preoperative [
    Lin JT; Li XM; Zhong WZ; Hou QY; Liu CL; Yu XY; Ye KY; Cheng YL; Du JY; Sun YQ; Zhang FG; Yan HH; Liao RQ; Dong S; Jiang BY; Liu SY; Wu YL; Yang XN
    Ann Nucl Med; 2024 Mar; 38(3):188-198. PubMed ID: 38145431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer.
    Yıldırım F; Yurdakul AS; Özkaya S; Akdemir ÜÖ; Öztürk C
    Clin Respir J; 2017 Sep; 11(5):602-611. PubMed ID: 26434685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment
    Satoh Y; Motosugi U; Saito A; Omiya Y; Onishi H
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818794934. PubMed ID: 30222060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E
    Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
    Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
    Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Value and Clinical Impact of Pretreatment FDG PET in Pulmonary Lymphoepithelioma-Like Carcinoma.
    Su TP; Ho KC; Wang CW; Lin CY; Liu CY; Yang CT; Yen TC
    Clin Nucl Med; 2019 Feb; 44(2):e68-e75. PubMed ID: 30608914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of metabolic tumor volume of pretreatment
    Kumasaka S; Nakajima T; Arisaka Y; Tokue A; Achmad A; Fukushima Y; Shimizu K; Kaira K; Higuchi T; Tsushima Y
    BMC Med Imaging; 2018 Nov; 18(1):46. PubMed ID: 30477476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary tumor standardized uptake value (SUVmax) measured on
    Hui Z; Wei F; Ren H; Xu W; Ren X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.